Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases through a China-based commercial organization and a global clinical pipeline. News for HCM centers on marketed oncology products such as FRUZAQLA and ELUNATE for fruquintinib, ORPATHYS for savolitinib, China regulatory actions, and partner-driven commercialization outside China.
Recurring updates also cover pipeline compounds including sovleplenib, HMPL-760 and HMPL-A580, clinical data presented at oncology meetings, and the company’s Antibody-Targeted Therapy Conjugate platform. Corporate items include annual results, product-license updates such as TAZVERIK in China, board and committee changes, and disclosures tied to HUTCHMED’s Nasdaq, AIM and HKEX listings and ADR structure.
Hutchison China MediTech Limited (HCM) announced that the Independent Data Monitoring Committee (IDMC) has completed an interim data review of the FRUTIGA study for fruquintinib. The trial, which focuses on patients with advanced gastric adenocarcinoma, will continue based on preset criteria. Fruquintinib is an oral inhibitor targeting VEGFR, designed to minimize off-target toxicities. The FRUTIGA trial aims to evaluate its efficacy when combined with paclitaxel for second-line treatment in patients who didn't respond to initial chemotherapy. Additional global studies for colorectal cancer are also planned.
Hutchison China MediTech (HCM) and BeiGene announced a clinical collaboration to evaluate the efficacy of combining HCM’s drug candidates, surufatinib and fruquintinib, with BeiGene’s tislelizumab for treating various solid tumors. The trials will take place in the U.S., Europe, China, and Australia. Both companies will support drug supply and development efforts. Tislelizumab aims to reduce negative effects on T effector cells, while fruquintinib enhances kinase selectivity to reduce off-target toxicities. Surufatinib is also under NDA review in China.
Hutchison China MediTech Limited (HCM) announced new analyses of savolitinib, surufatinib, and fruquintinib, to be presented at the ASCO20 Virtual Scientific Program from May 29-31, 2020. The company will hold a conference call on June 1 to discuss results. Key studies include a Phase II study of savolitinib for non-small cell lung cancer and a Phase III trial comparing savolitinib with sunitinib for renal cell carcinoma. Surufatinib's efficacy in neuroendocrine tumors will also be highlighted, reflecting HCM's commitment to innovative cancer therapies.
Hutchison China MediTech Limited (Nasdaq/AIM: HCM) announced that CEO Mr. Christian Hogg will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on May 14, 2020, at 9:40 a.m. EDT. The event will be streamed live and can be accessed via the company's website. Following this conference, Chi-Med's senior management will hold one-on-one meetings at several upcoming events, including the Citi Virtual Pan-Asia Regional Investor Conference and Jefferies Global Healthcare Conference. Chi-Med aims to advance its pipeline of cancer therapies.